GlassScriptPhysician profile
James Harrison Raybourn
NPI 1871736595
$27,495.04
in general payments reported to CMS, 2019-2025
41 companies · $8,098 in 2025
The $8,098 reported for 2025 was more than what 93% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $456 · 2021: $281 · 2022: $528 · 2023: $1,005 · 2024: $17K · 2025: $8,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $22K · Food and Beverage: $3,366 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $22,071.43 |
| Food and Beverage | $3,366.31 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Central Indiana Urs Consumables, LLC | $22,071.43 | 2024-2025 | Dornier Medtech, Cvac Aspiration System, Dornier Medtech |
| Bayer Healthcare Pharmaceuticals INC. | $817.70 | 2019-2025 | |
| Janssen Biotech, INC. | $640.68 | 2019-2025 | Erleada, Akeega |
| Dendreon Pharmaceuticals LLC | $533.21 | 2019-2025 | Provenge |
| Pfizer INC. | $426.83 | 2019-2025 | |
| Astellas Pharma US INC | $377.02 | 2019-2025 | Xtandi, Myrbetriq |
| Accord Healthcare, INC. | $280.28 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $258.69 | 2023-2025 | Orgovyx, Gemtesa |
| Genzyme Corporation | $179.48 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $172.32 | 2020-2025 | Lynparza |
| Sun Pharmaceutical Industries INC. | $170.30 | 2022-2025 | Yonsa |
| Myovant Sciences INC. | $133.02 | 2021-2022 | |
| Tolmar, INC. | $124.22 | 2023-2025 | Eligard |
| Amgen INC. | $119.57 | 2019-2022 | |
| Abbvie INC. | $118.08 | 2019-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $113.47 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $100.52 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Blue Earth Diagnostics | $98.68 | 2019-2024 | |
| Progenics Pharmaceuticals, INC. | $97.39 | 2024-2025 | |
| Urogen Pharma, INC. | $95.10 | 2023-2024 | Jelmyto |
| Laborie Medical Technologies Corp. | $62.13 | 2024 | Optilume Bph Drug Coated Balloon Catheter, Endosheath Technology |
| Rochester Medical Corporation | $48.45 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $46.77 | 2023 | Bard Urinary Drainage Bag |
| Ferring Pharmaceuticals INC. | $43.21 | 2019-2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $35.90 | 2022 | |
| Davol INC. | $34.50 | 2020-2022 | |
| Coloplast Corp | $34.14 | 2024-2025 | |
| Civco Medical Instruments | $28.67 | 2025 | |
| Becton, Dickinson and Company | $24.97 | 2024 | Bard Urinary Drainage Bag |
| Inspire Medical Systems, INC. | $24.79 | 2024 | Inspire |
| Tempus Ai, INC | $20.57 | 2024 | |
| Sanofi-Aventis U.S. LLC | $19.63 | 2020 | |
| Cycle Pharmaceuticals INC | $19.19 | 2025 | Venxxiva |
| Medtronic, INC. | $18.72 | 2025 | Altaviva |
| Myriad Genetic Laboratories, INC. | $16.73 | 2023 | Prolaris |
| Cook Medical LLC | $16.02 | 2023 | Tornado |
| Vertex Pharmaceuticals Incorporated | $15.59 | 2025 | |
| Olympus America INC. | $15.09 | 2025 | Itind System |
| Sanara Medtech INC. | $14.70 | 2022 | |
| Urovant Sciences INC | $14.63 | 2022 | |
| Clinigen, INC. | $12.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$47,040.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Raybourn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.